Paris, France, January 4, 2023, 7:30 am CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the Company will participate in the following investor conferences in January 2023:

 

26th ODDO BHF Forum

January 9 – 10, 2023 – Virtual

Bernard Gilly, Co-Founder & Chief Executive Officer, and Thomas Gidoin, Chief Financial Officer, will host investor meetings.

 

Invest Securities Biomed Forum

January 24, 2023 – Paris, France

Thomas Gidoin, Chief Financial Officer, will attend in person and host investor meetings.

 

11th Degroof Petercam Healthcare Conference

January 25, 2023 – Virtual

Thomas Gidoin, Chief Financial Officer, will host investor meetings.

Contacts